Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Tomazos · SciRah

Researcher profile · Semantic Scholar

I. Tomazos

Share profile

I. Tomazos — researcher profile on SciRah

h-index: 2
Works: 23
Citations: 20

Most-cited papers

PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME
A. Levy, P.G.F. Chen, I. Tomazos
2019Value in Health7 citations Open access
Semantic Scholar
PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM
A. Lloyd, K. Gallop, Shehzad Ali, K. Myrén +5 more
2019Value in Health5 citations Open access
Semantic Scholar
CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States
A. Salvucci, C. Qian, L. Powell, D. Lynch +3 more
2023Value in Health1 citations Open access
Semantic Scholar
PCR84 The Daily Life and Psychosocial Impacts of Friedreich Ataxia: A Qualitative Study of Patient Lived Experiences
A. Bever, S. Szabo, J. Vallortigara, P. Giunti +3 more
2023Value in Health1 citations Open access
Semantic Scholar
PRO77 Preliminary Characterization of Eculizumab Treatment Patterns, Preceding Disease Triggers and Supportive Therapies in Atypical Hemolytic Uremic Syndrome: A US Claims Database Analysis
I. Tomazos, A. Levy, C. Faria
2021Value in Health1 citations Open access
Semantic Scholar
PRO33 Ravulizumab Reduces Productivity Losses Versus Eculizumab for Treating Atypical Hemolytic Uremic Syndrome: A 'cost Consequence' Analysis in 4 Countries
A. Levy, P.G.F. Chen, I. Tomazos
20201 citations Open access
Semantic Scholar
PRO36 A US COST-MINIMIZATION MODEL COMPARING LIFETIME PER-PATIENT COSTS FOR RAVULIZUMAB AND ECULIZUMAB FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME
Y. Wang, K. Johnston, E. Popoff, Karl-Johan Myren +3 more
20201 citations Open access
Semantic Scholar
PRO32 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN FIVE COUNTRIES
A. Lloyd, K. Gallop, Shehzad Ali, K. Myrén +5 more
20201 citations Open access
Semantic Scholar
PRO33 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Thomas O’Connell, M. Buessing, Scott J. Johnson, L. Tu +2 more
2019Value in Health1 citations Open access
Semantic Scholar
PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
T. OConnell, M. Buessing, L. Tu, I. Tomazos +2 more
2019Value in Health1 citations Open access
Semantic Scholar
PCR103 ESTIMATION OF HEALTH-STATE UTILITY VALUES IN PHENYLKETONURIA (PKU), VIA CLINICAL-EXPERT PROXY ASSESSMENT WITH A GENERIC MEASURE (SF-12V2) OF PATIENT-REPORTED IMPACTS FROM A DISEASE-SPECIFIC MEASURE (PKU-QOL): INTERIM RESULTS
Thomas O’Connell, Suzanne Hollander, Suresh Vijay, N. Longo +3 more
2026Value in Health0 citations
Semantic Scholar
CO150 SAFETY OF SEPIAPTERIN AND PEGVALIASE FOR THE TREATMENT OF PHENYLKETONURIA (PKU): A SIMULATED TREATMENT COMPARISON (STC)
F. O’Sullivan, Juan Pablo Díaz-Martínez, I. Schwartz, Karissa M. Johnston +1 more
2026Value in Health0 citations
Semantic Scholar
CO182 Intelligence Quotient (IQ) Scores Among Early-Treated Phenylketonuria (PKU) Patients: Results from a Systematic Literature Review (SLR)
F. O'sullivan, I. Tomazos, F. V. van Spronsen, S. Szabo +7 more
2024Value in Health0 citations Open access
Semantic Scholar
PCR30 The Burden of Familial Chylomicronemia Syndrome (FCS) in Brazilian Patients – A Pilot Qualitative Study
F. Vicente, E. de Paula, Darryl D’silva, I. Tomazos +2 more
2023Value in Health0 citations
Semantic Scholar
CO142 A Retrospective Study Characterizing Age at Key Clinical Disease Indicators Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States
A. Salvucci, C. Qian, L. Powell, D. Lynch +3 more
2023Value in Health0 citations
Semantic Scholar
RWD99 The Clinical Burden of Friedreich Ataxia: A Retrospective Claims Analysis in the United States
L. Powell, D. Lynch, C. Qian, A. Salvucci +3 more
2023Value in Health0 citations
Semantic Scholar
SA70 Patient-Reported Outcomes and Daily Activity Assessed with a Digital Wearable Device (FITBIT™) in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: The Reveal Study
E. A. Griffiths, A. Wang, I. Tomazos, J. Min +4 more
2023Value in Health0 citations
Semantic Scholar
RWD128 A Retrospective Claims Analysis Characterizing Health Care Resource Use Among Patients with Friedreich Ataxia in the United States
C. Qian, D. Lynch, L. Powell, A. Salvucci +3 more
2023Value in Health0 citations
Semantic Scholar
PCR139 'We Have Conversations That Other Couples Don′t Have to Have:' A Qualitative Study of the Impact of Caregiving in Friedreich Ataxia (FA)
S. Szabo, A. Bever, D. Lynch, G. Vasco +3 more
2023Value in Health0 citations
Semantic Scholar
POSA380 Qualitative Development of Surveys to Assess Real-World Patient and Caregiver Perspectives of Atypical Hemolytic Uremic Syndrome Treatment Preferences and Impact
Y. Wang, M. Chladek, K. Garlo, L. Lloyd-Price +3 more
2022Value in Health0 citations Open access
Semantic Scholar
PRO30 Utility Values Associated with Treatment Attributes for Atypical Hemolytic Uremic Syndrome: A Discrete Choice Experiment in 5 Countries
K. Williams, A. Daniel, P. Chen, K. Myrén +5 more
20200 citations Open access
Semantic Scholar
Comparative Efficacy of Ravulizumab and Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome: An Indirect Comparison Using Clinical Trial Data
E. Rondeau, A. Hatswell, S. Cataland, Peter Chen +8 more
2020Journal of the American Society of Nephrology0 citations Open access
Semantic Scholar
PRO19 THE IMPACT OF ECULIZUMAB ON HOSPITALIZATION AND LENGTH OF STAY IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME: A US CLAIMS DATABASE ANALYSIS
I. Tomazos, K. Garlo, C. Faria, Y. Wang +2 more
20200 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Salvucci×4
Invite
A. Salvucci — researcher profile on SciRah
L. Powell×4
Invite
L. Powell — researcher profile on SciRah
D. Lynch×4
Invite
D. Lynch — researcher profile on SciRah
G. Vasco×4
Invite
G. Vasco — researcher profile on SciRah

×4

Invite

K. Johnston — researcher profile on SciRah

Invite

Y. Wang — researcher profile on SciRah

Invite

A. Levy — researcher profile on SciRah

Invite

A. Lloyd — researcher profile on SciRah

Invite

K. Myrén — researcher profile on SciRah

Invite

K. Anokhina — researcher profile on SciRah

Invite

S. Szabo — researcher profile on SciRah

Invite

C. Faria — researcher profile on SciRah